Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Richard R. Schumacher"'
Publikováno v:
Annals of the New York Academy of Sciences. 83:217-226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae325737d63a063c3d85f5e98754f57
https://doi.org/10.1111/j.1749-6632.1960.tb40894.x
https://doi.org/10.1111/j.1749-6632.1960.tb40894.x
Autor:
Joseph Loscalzo, Eric J. Topol, Victor Gurewich, Richard R. Schumacher, Herbert J. Levine, Eugene Braunwald, James M. Kirshenbaum, Raymond D. Bahr, John T. Flaherty, Dennis W. Wahr
Publikováno v:
The American Journal of Cardiology. 68:1564-1569
The effect of simultaneous infusions of low-dose recombinant tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA, pro-urokinase) on coronary arterial thrombolysis was investigated in 23 patients trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b0d3432d5572efc1871d3a196344a01
https://doi.org/10.1016/0002-9149(91)90310-h
https://doi.org/10.1016/0002-9149(91)90310-h
Autor:
David A. Tate, Timothy C. Nichols, David H. Cooke, Richard R. Schumacher, Sam L. Teichman, Stanley D. Bleich
Publikováno v:
The American journal of cardiology. 66(20)
Infarct artery patency rates at 90 minutes after coronary thrombolysis using recombinant tissue-type plasminogen activator (rt-PA) with and without concurrent heparin anticoagulation have been shown to be comparable. The contribution of heparin to ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21bc4283c0493874bed279cdc0c94163
https://pubmed.ncbi.nlm.nih.gov/2123602
https://pubmed.ncbi.nlm.nih.gov/2123602
Autor:
Elliott B. Grossbard, Charles R. Taylor, Margaret E. Tufte, Akira Nishikawa, Richard W. Smalling, Desire Collen, Eric J. Topol, Douglas C. Morris, Henry A. Liberman, Richard R. Schumacher, William W. O'Neill
Publikováno v:
Journal of the American College of Cardiology. 9:1205-1213
A new, predominantly single chain preparation of recombinant tissue-type plasminogen activator was evaluated to determine coronary thrombolytic efficacy in 100 patients with acute myocardial infarction. At 3.6 +/- 1.2 hours (mean +/- SD) from symptom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6747d3bf7c3e4ce150089f3cf89c02f0
https://doi.org/10.1016/s0735-1097(87)80457-6
https://doi.org/10.1016/s0735-1097(87)80457-6
Publikováno v:
Circulation. 39(1)
The case of a 73-year-old white man with corrected transposition of the great vessels and associated mitral and mild aortic regurgitation is reported. The patient's survival was the longest of any patient with this defect reported to date. Although t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06afd036c8657993865d12dd1460584
https://pubmed.ncbi.nlm.nih.gov/5782811
https://pubmed.ncbi.nlm.nih.gov/5782811
Publikováno v:
Circulation. 37(6)
The intravenous administration of 50 mg of lidocaine as a single bolus to four patients with heart disease did not result in a significant change in cardiac output or left ventricular end-diastolic pressure (LVEDP). Two patients had moderate decrease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba37d14707e4cbc12257923fa7ed8e1a
https://pubmed.ncbi.nlm.nih.gov/4871180
https://pubmed.ncbi.nlm.nih.gov/4871180
Autor:
Gross V; Pressure BioSciences, Inc., South Easton, MA 02375, USA., Lazarev A, Lawrence N, Schumacher R
Publikováno v:
BioTechniques [Biotechniques] 2008 Jul; Vol. 45 (1), pp. 99-100.